Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | PLK4 | O00444 | 1/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | LTK | P29376 | 1/20 | 0.34 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL817343 | 0.83 | CES1 (0.41) | MAOAMAOBCES1ALDH1A1KDM4E | |
| SCHEMBL7034653 | 0.80 | MAOA (0.32) | MAOAMAOBBCHECES1 | |
| SCHEMBL4034579 | 0.79 | HTR2A (0.32) | MAOA | |
| SCHEMBL28445132 | 0.77 | HRH1 (0.35) | MAOAMAOBGABRPGABRDGABRA1 | |
| SCHEMBL30477992 | 0.75 | MAOA (0.37) | MAOAMAOBBCHECES1ALDH1A1 | |
| SCHEMBL28456875 | 0.75 | MAOA (0.37) | MAOAMAOBBCHECES1ALDH1A1 | |
| SCHEMBL13797871 | 0.72 | — | — | |
| SCHEMBL11661884 | 0.70 | ALDH1A1 (0.44) | MAOABCHECES1ALDH1A1KDM4E | |
| SCHEMBL5027873 | 0.70 | MAOA (0.46) | MAOABCHECES1ALDH1A1METAP2 | |
| SCHEMBL29795069 | 0.70 | MAOA (0.46) | MAOABCHECES1ALDH1A1METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906651-B2 | Catalytic system of asymmetric reactions in aqueous media; react a silicon enolate and formaldehyde; catalyst obtained by mixing chiral ligands with scandium triflate | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-03-15 | — | — | US | disclosed |
| US-7541307-B2 | Method for manufacturing an optically active hydroxymethylated compound and a catalyst therefore | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20080269496-A1 | Method for Producing Optically Active Hydroxymethylated Compounds | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080139835-A1 | Method for Manufacturing an Optically Active Hydroxymethylated Compound and a Catalyst Therefore | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139835-A1 | Method for Manufacturing an Optically Active Hydroxymethylated Compound and a Catalyst Therefore | OGFOD1, POF1B, EEF1D | MAOA 1216/4885MAOB 510/4885BCHE 414/4885 |
| US-20080269496-A1 | Method for Producing Optically Active Hydroxymethylated Compounds | TET1, TET3, CYP3A4 | MAOA 278/4885MAOB 220/4885BCHE 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.